Mediators of Inflammation

Mediators of Inflammation / 2007 / Article

Research Article | Open Access

Volume 2007 |Article ID 050180 | https://doi.org/10.1155/2007/50180

Chao Zhang, Gui-hua Hou, Jian-kui Han, Jing Song, Ting Liang, "Radioiodine Labeled Anti-MIF McAb: A Potential Agent for Inflammation Imaging", Mediators of Inflammation, vol. 2007, Article ID 050180, 5 pages, 2007. https://doi.org/10.1155/2007/50180

Radioiodine Labeled Anti-MIF McAb: A Potential Agent for Inflammation Imaging

Received21 Jun 2007
Accepted22 Aug 2007
Published17 Oct 2007

Abstract

Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine that may play a role in the pathogenesis of inflammation. Radiolabeled anti-MIF McAb can be used to detect in vivo inflammatory changes. The objective of this study was to investigate in vivo biology of radioiodinated anti-MIF McAb using the inflammation model mice. Anti-MIF McAb was radioiodinated with Na125I by Iodogen method. Animal models were induced in the mice by intramuscular injection of S. aureus, E. coli, and turpentine oil. The biodistribution studies with radioiodinated anti-MIF McAb were performed on inflammation mice. The relationship between inflammatory lesions and anti-MIF McAb binding was investigated using the percent of injected dose per gram tissue (% ID/g) of tissue samples and whole-body autoradiography. The radioactivity of 125I-anti-MIF McAb in the inflammatory tissue increased gradually for three inflammation models. The highest uptake was found in S. aureus group and the lowest was in E. coli group. The uptake in turpentine oil group was average. Whole-body autoradiography showed that all inflammation foci could be visualized clearly from 24 hours after injection, but 48 hours images were much clearer in accordance with the high T/NT ratio. These results demonstrate the ability of radioiodinated anti-MIF McAb to measure in vivo inflammatory events represented by high expression of MIF and suggests that radiolabeled anti-MIF McAb warrants further investigation as a potential inflammation-seeking agent for imaging to detect inflammatory disorders.

References

  1. B. R. Bloom and B. Bennett, “Mechanism of a reaction in vitro associated with delayed-type hypersensitivity,” Science, vol. 153, no. 3731, pp. 80–82, 1966. View at: Publisher Site | Google Scholar
  2. J. R. David, “Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction,” Proceedings of the National Academy of Sciences of the United States of America, vol. 56, no. 1, pp. 72–77, 1966. View at: Publisher Site | Google Scholar
  3. J. Bernhagen, T. Calandra, R. A. Mitchell et al., “MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia,” Nature, vol. 365, no. 6448, pp. 756–759, 1993. View at: Publisher Site | Google Scholar
  4. C. M. Denkinger, C. Metz, G. Fingerle-Rowson, M. D. Denkinger, and T. G. Forsthuber, “Macrophage migration inhibitory factor and its role in autoimmune diseases,” Archivum Immunologiae et Therapiae Experimentalis, vol. 52, no. 6, pp. 389–400, 2004. View at: Google Scholar
  5. T. Calandra and T. Roger, “Macrophage migration inhibitory factor: a regulator of innate immunity,” Nature Reviews Immunology, vol. 3, no. 10, pp. 791–800, 2003. View at: Publisher Site | Google Scholar
  6. E. Lolis, “Glucocorticoid counter regulation: macrophage migration inhibitory factor as a target for drug discovery,” Current Opinion in Pharmacology, vol. 1, no. 6, pp. 662–668, 2001. View at: Publisher Site | Google Scholar
  7. Y. P. De Jong, A. C. Abadia-Molina, A. R. Satoskar et al., “Development of chronic colitis is dependent on the cytokine MIF,” Nature Immunology, vol. 2, no. 11, pp. 1061–1066, 2001. View at: Publisher Site | Google Scholar
  8. F. A. Bozza, R. N. Gomes, A. M. Japiassú et al., “Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis,” Shock, vol. 22, no. 4, pp. 309–313, 2004. View at: Publisher Site | Google Scholar
  9. T. Ohkawara, J. Nishihira, H. Takeda et al., “Amelioration of dextran sulfate sodium-induced colitis by anti-macrophage migration inhibitory factor antibody in mice,” Gastroenterology, vol. 123, no. 1, pp. 256–270, 2002. View at: Publisher Site | Google Scholar
  10. Y. Sakai, A. Masamune, A. Satoh, J. Nishihira, T. Yamagiwa, and T. Shimosegawa, “Macrophage migration inhibitory factor is a critical mediator of severe acute pancreatitis,” Gastroenterology, vol. 124, no. 3, pp. 725–736, 2003. View at: Publisher Site | Google Scholar
  11. M. Leech, C. Metz, P. Hall et al., “Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids,” Arthritis and Rheumatism, vol. 42, no. 8, pp. 1601–1608, 1999. View at: Publisher Site | Google Scholar
  12. N. Yabunaka, J. Nishihira, Y. Mizue et al., “Elevated serum content of macrophage migration inhibitory factor in patients with type 2 diabetes,” Diabetes Care, vol. 23, no. 2, pp. 256–258, 2000. View at: Publisher Site | Google Scholar
  13. F. Nicoletti, A. Créange, D. Orlikowski et al., “Macrophage migration inhibitory factor (MIF) seems crucially involved in Guillain-Barré syndrome and experimental allergic neuritis,” Journal of Neuroimmunology, vol. 168, no. 1-2, pp. 168–174, 2005. View at: Publisher Site | Google Scholar
  14. M. Niino, A. Ogata, S. Kikuchi, K. Tashiro, and J. Nishihira, “Macrophage migration inhibitory factor in the cerebrospinal fluid of patients with conventional and optic-spinal forms of multiple sclerosis and neuro-Behçet’s disease,” Journal of the Neurological Sciences, vol. 179, no. 1-2, pp. 127–131, 2000. View at: Publisher Site | Google Scholar
  15. C. J. van der Laken, O. C. Boerman, W. J. G. Oyen, M. T. P. van de Ven, J. W. M. van der Meer, and F. H. M. Corstens, “Scintigraphic detection of infection and inflammation: new developments with special emphasis on receptor interaction,” European Journal of Nuclear Medicine, vol. 25, no. 5, pp. 535–546, 1998. View at: Publisher Site | Google Scholar
  16. W. Becker, “The contribution of nuclear medicine to the patient with infection,” European Journal of Nuclear Medicine, vol. 22, no. 10, pp. 1195–1211, 1995. View at: Google Scholar
  17. S. Vinjamuri, A. V. Hall, K. K. Solanki et al., “Comparison of T99mc infecton imaging with radiolabelled white-cell imaging in the evaluation of bacterial infection,” Lancet, vol. 347, no. 8996, pp. 233–235, 1996. View at: Publisher Site | Google Scholar
  18. E. P. Krenning, D. J. Kwekkebomm, S. Pauwels, L. K. Kvols, and J. C. Reubi, “Somatostatin receptor scintigraphy,” in Nuclear Medicine Annual, pp. 1–50, Raven Press, New York, NY, USA, 1995. View at: Google Scholar
  19. M. R. Plucher and P. J. Blower, “Labelling of lekocytes with colloidal tecnetium-99m-SnF2: an investigation of the labeling process by autoradiography,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 22, no. 2, pp. 101–107, 1995. View at: Publisher Site | Google Scholar
  20. G. Ferro-Flores, C. Arteaga de Murphy, M. Pedraza-López et al., “In vitro and in vivo assessment of T99mc-UBI specificity for bacteria,” Nuclear Medicine and Biology, vol. 30, no. 6, pp. 597–603, 2003. View at: Publisher Site | Google Scholar
  21. G. W. Visser, R. P. Klok, J. W. K. Gebbinck, T. Ter Linden, G. A. van Dongen, and C. F. Molthoff, “Optimal quality I131-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN,” Journal of Nuclear Medicine, vol. 42, no. 3, pp. 509–519, 2001. View at: Google Scholar
  22. G. C. Jayson, J. Zweit, A. Jackson et al., “Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies,” Journal of the National Cancer Institute, vol. 94, no. 19, pp. 1484–1493, 2002. View at: Publisher Site | Google Scholar
  23. I. Verel, G. W. M. Visser, R. Boellaard et al., “Quantitative Z89r immuno-PET for in vivo scouting of Y90-labeled monoclonal antibodies in xenograft-bearing nude mice,” Journal of Nuclear Medicine, vol. 44, no. 10, pp. 1663–1670, 2003. View at: Google Scholar
  24. E. F. Morand, “New therapeutic target in inflammatory disease: macrophage migration inhibitory factor,” Internal Medicine Journal, vol. 35, no. 7, pp. 419–426, 2005. View at: Publisher Site | Google Scholar
  25. D. Aeberli, M. Leech, and E. F. Morand, “Macrophage migration inhibitory factor and glucocorticoid sensitivity,” Rheumatology, vol. 45, no. 8, pp. 937–943, 2006. View at: Publisher Site | Google Scholar

Copyright © 2007 Chao Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views102
Downloads359
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.